EMD Serono and MD Anderson Cancer Center Enter Three-Year Strategic Collaboration
Merck KGaA, Darmstadt, Germany | January 09, 2017
EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, and The University of Texas MD Anderson Cancer Center today announced a three-year strategic collaboration, with the aim of more quickly advancing the development of investigational cancer therapies in four cancers – breast, colorectal, glioblastoma and leukemia.